<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6565">
  <stage>Registered</stage>
  <submitdate>22/06/2017</submitdate>
  <approvaldate>22/06/2017</approvaldate>
  <nctid>NCT03198013</nctid>
  <trial_identification>
    <studytitle>A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males</studytitle>
    <scientifictitle>Placebo-Controlled, Double-Blind, Ascending Single and Multiple Oral Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-791826 and to Assess Its Marker Specific Pharmacodynamics in Relation to Prednisolone in Healthy Males</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IM125-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immunoscience</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Prednisolone
Treatment: drugs - BMS-791826
Treatment: drugs - Placebo

Experimental: Module A - Single Ascending Dose

Experimental: Module B - Multiple Ascending Dose


Treatment: drugs: Prednisolone
Specified dose on specified days

Treatment: drugs: BMS-791826
Specified dose on specified days

Treatment: drugs: Placebo
Specified dose on specified days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Adverse Events (AEs) - safety and tolerability</outcome>
      <timepoint>Up to 34 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of serious adverse events (SAEs) - safety and tolerability</outcome>
      <timepoint>Up to 34 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male subjects as determined by no clinically significant deviation from normal
             in medical history, physical examination, electrocardiograms (ECGs), and clinical
             laboratory determinations

          -  Body Mass Index (BMI) of 18 to 30 kilogram / square meter (kg/m2), inclusive

          -  Signed informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer />
    <exclusivecriteria>-  Sexually active fertile men not using effective birth control (barrier contraception)
             if their partners are women of childbearing potential (WOCBP)

          -  Any significant acute or chronic medical illness

          -  History of Gilbert's disease

        Other protocol inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>11/11/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>120</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/05/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Local Insitution - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety, PK, PD, of BMS-791826 and to assess its
      marker specific PD in relation to Prednisolone in healthy male subjects</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03198013</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>